Scholar Rock Holding Corp

SRRK remains in a Stage 2 advancing uptrend with rising EMAs but shows a Bullish Exhaustion candle at recent highs. The current pullback into the rising 9-, 20-, and 50-day EMAs suggests waning momentum. Under a speculative framework, entries should be deferred until clear acceptance or resilience at these dynamic support levels emerges.

• ↑FDA accepted BLA with PDUFA on Sep 30, 2026; two fill-finish sites ready.
• ↑Q1 2026 cash balance of $480M (plus $100M debt drawdown, $98M ATM) fuels launch.
• ↓Q1 2026 OPEX of $102M (high stock-based comp) underscores weak profitability factors.